PharmaEngine, Inc.

TPEX:4162 Stock Report

Market Cap: NT$7.9b

PharmaEngine Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Hong-Ren Wang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.7yrs
CEO ownership0.02%
Management average tenureno data
Board average tenure5.1yrs

Recent management updates

Recent updates

Analysis Article • Mar 30

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Is PharmaEngine, Inc. ( GTSM:4162 ) a good dividend stock? How can we tell? Dividend paying companies with growing...
Analysis Article • Feb 18

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

We think intelligent long term investing is the way to go. But no-one is immune from buying too high. To wit, the...
Analysis Article • Jan 14

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

PharmaEngine (GTSM:4162) has had a rough three months with its share price down 13%. To decide if this trend could...
Analysis Article • Dec 10

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...

CEO

Hong-Ren Wang

5.7yrs
Tenure

Mr. Hong-Ren Wang, Ph D., is President of PharmaEngine, Inc. since January 20, 2021 and serves as Chief Executive Officer. Mr. Wang holds Ph.D. degree in Materials Science and Engineering from Massachusett...

Board Members

NamePositionTenureCompensationOwnership
Wen-Hung Hsu
Representative Directorno dataNT$2.06mno data
Jan-Yau Hsu
Chairman1.3yrsNT$6.50mno data
Rui-Wen Wu
Representative Director8.7yrsNT$2.06mno data
Yi-Hui Lin
Representative Director8.3yrsNT$2.06mno data
Chih-Li Wang
Independent Director7.3yrsNT$1.68m0.0021%
NT$ 165.3k
Ming-Feng Hou
Director5.1yrsNT$2.07mno data
Chien-Huang Lin
Independent Director5.1yrsNT$1.68mno data
Ming-Daw Chang
Independent Directorno dataNT$1.68mno data
Ming-Shiang Wu
Representative Directorno dataNT$2.06mno data
Pau-Chu Lo
Independent Director1.3yrsno data0.019%
NT$ 1.5m
Wen-Ta Chiu
Independent Director1.3yrsno datano data
5.1yrs
Average Tenure

Experienced Board: 4162's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 17:15
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaEngine, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nam ParkHSBC
Hengyu FuMasterlink Securities Investment Advisory
Toshinori KatsukiNomura Securities Co. Ltd.